Physician profile
William Cheung
NPI 1255775797
$1,945.79
in general payments reported to CMS, 2019-2025
17 companies · $513 in 2025
The $513 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $223 · 2022: $196 · 2023: $566 · 2024: $448 · 2025: $513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,526.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $314.70 | 2023 | Farxiga, Lokelma |
| Novo Nordisk INC | $306.08 | 2022-2025 | Ozempic |
| Travere Therapeutics, INC. | $293.34 | 2023-2025 | Filspari |
| Amgen INC. | $244.69 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Mallinckrodt Hospital Products INC. | $145.63 | 2024 | Terlivaz |
| Sumitomo Pharma America, INC. | $143.67 | 2024-2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $112.20 | 2023-2025 | |
| Mallinckrodt Enterprises LLC | $99.99 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $62.31 | 2023 | Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.34 | 2025 | Jardiance |
| Calliditas Therapeutics US INC. | $36.92 | 2023-2025 | Tarpeyo |
| Ardelyx, INC. | $29.75 | 2025 | Ibsrela |
| Lilly USA, LLC | $26.54 | 2024 | Jardiance |
| Ani Pharmaceuticals, INC. | $24.89 | 2023 | Purified Cortrophin Gel |
| Fresenius USA Marketing, INC. | $23.23 | 2024 | Velphoro |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $22.61 | 2023 | Lupkynis |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.90 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Cheung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.